Increased dosage of DYRK1A results in impairment of mitochondrial function and congenital heart disease pathology in mice with DS, suggesting that DYRK1A may be a useful therapeutic target for treating this common human condition. The gene discussed is DYRK1A; the disease is congenital heart disease.